Company History

bioTheranostics has a rich history of innovation

2000
Arcturus Applied Genomics (AAG) starts in San Diego

2002
RiboAmp first-in-market linear RNA amplification

2003
Paradise first-in-market RNA amplification from formalin-fixed paraffin-embedded tissues

First to discover gene expression signatures associated with stage and grade in breast cancer discovery of molecular grade published in Proceedings of National Academy of Sciences in partnership with Massachusetts General Hospital Cancer Center and Harvard Medical School

2004
Discovery of H/I to predict clinical outcome in breast cancer patients published in CancerCell in partnership with Massachusetts General Hospital Cancer Center and Harvard Medical School

First-in-market cancer classification microarray test licensed to Agendia

2006
Arcturus sold to MDC/MDS becomes AviaraDx

H/I validated by Mayo Clinic with publication in Clinical Cancer Research

H/I validated Baylor College of Medicine with publication in Journal of Clinical Oncology

First-in-market cancer classification test RT-PCR licensed to LabCorp Quest

Publication of 92-Gene RT-PCR assay in Archives of Pathology and Laboratory Medicine

2007
CLIA-certified CAP-accreditation – high complexity clinical lab established

AviaraDx obtains $8M in first round financing

Netherlands Group shows H/I is prognostic and predictive in Journal of Clinical Oncology

Swedish group shows H/I predicts endocrine benefit in Breast Cancer Research and Treatment

2008
bioMérieux buys AviaraDx; forms bioTheranostics

Demonstrated that H/I + MGI is a powerful prognostic for recurrence in Clinical Cancer Research

CancerTYPE ID clinical study of latent primary cases completed

CancerTYPE ID Prospective Trial with the Sarah Cannon Research Institute initiated

Obtain allowance of claims from United States Patent and Trademark Office first H/I patent